TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04775875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study: NCT00094744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: adhesive eye patch used to cover the sound eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: adhesive eye patch used to cover the sound eye
Study: NCT03379805

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Fluorescence Imaging
Description: The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Fluorescence Imaging
Description: The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: The anatomy is described using non-contrast MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: The anatomy is described using non-contrast MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: The capillary filtration rate is measured using plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: The capillary filtration rate is measured using plethysmography
Study: NCT01193868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01087073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Training
Description: Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Outreach
Description: The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
Study: NCT00772343

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: 0.5 mL, intramuscular on Days 0, 7, and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine
Description: 0.5 mL, intramuscular on Days 0, 7, and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine with adjuvant
Description: 0.5 mL, intramuscular on Days 0, 7, and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine
Description: 0.5 mL, intramuscular on Days 0, 7, and 28
Study: NCT03467191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: target BAC .08%
Study: NCT04338542

Intervention type: GENETIC
Intervention: Tumor biobsies analysis
Description: Analysis on archived tumor biopsies

Intervention type: GENETIC
Intervention: Tumor biobsies analysis
Description: Analysis on archived tumor biopsies
Study: NCT02966665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
Study: NCT03467191

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo beverage
Study: NCT01717261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Pre-Operative Radiation Therapy
Description: Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
Study: NCT02649998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
Study: NCT04338542

Intervention type: GENETIC
Intervention: Tumor biobsies analysis
Description: Analysis on archived tumor biopsies
Study: NCT00428285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
Study: NCT00605228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Description: 2L Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COLOPEG
Description: 4L Drug
Study: NCT02541994

Intervention type: DEVICE
Group type: OTHER
Intervention: Pachette3
Description: Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lenstar-Think
Description: Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
Study: NCT04519476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Immunomodulatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Glucocorticoid, steroid
Study: NCT04224909

Intervention type: DIAGNOSTIC_TEST
Intervention: Video Head Impulse Test
Description: Diagnosis of dysfunction of the semicircular canals using the vHIT
Study: NCT04313309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
Study: NCT03266367

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil gelatinase-associated lipocalin (NAGL)
Description: Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil gelatinase-associated lipocalin (NAGL)
Description: Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
Study: NCT02280109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Gel
Description: single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Film
Description: single dose of 1.3% tenofovir film (equivalent to 40 mg)
Study: NCT04631016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 1
Study: NCT00645736

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02966665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
Study: NCT03442933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Road Cycling Time Trial
Description: The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Road Cycling Time Trial
Description: The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Mountain Biking Time Trial
Description: The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Mountain Biking Time Trial
Description: The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
Study: NCT00398086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.
Study: NCT02454296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block with lidocaine
Description: Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham paracervical block
Description: A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
Study: NCT04026308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety Net App
Description: The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
Study: NCT05188911

Intervention type: DRUG
Intervention: Abiraterone
Description: Patients would be treated with 1000mg abiraterone qd.

Intervention type: DRUG
Intervention: Prednisone
Description: Patients would be treated with 5mg prednisone bid.

Intervention type: DRUG
Intervention: Androgen deprivation therapy
Description: Patients would get medical or surgical castration.
Study: NCT00959764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Calcitonin Tablets
Description: Oral Calcitonin tablets along with matching placebo intranasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Calcitonin
Description: Intranasal Calcitonin Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets and placebo intranasal spray
Description: Oral Placebo Tablets/Intranasal placebo spray
Study: NCT00398086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion over 30 minutes.
Study: NCT02966665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
Study: NCT01887613

Intervention type: DRUG
Intervention: Regnite
Description: oral
Study: NCT00316706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)
Description: Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
Study: NCT01420913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300mg a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg a day
Study: NCT03803358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training with non-invasive ventilation
Description: In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard exercise training without NIV
Description: In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
Study: NCT01393665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNEL capsule
Description: hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00656058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair (Montelukast Sodium)
Description: Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
Study: NCT04305509

Intervention type: OTHER
Intervention: no intervention
Description: no intervention